Course Description
Antipsychotic treatment decisions often extend beyond the boundaries of clinical guidelines, requiring psychiatric pharmacists to navigate complex scenarios where evidence is limited and individualized care is essential. Through a lively debate format, expert faculty will examine controversial treatment decisions, including antipsychotic polypharmacy versus clozapine monotherapy, selecting among long-acting injectable antipsychotics (LAI), and managing inadequate response to LAI therapy. Participants will explore the risks, benefits, and evidence supporting competing treatment approaches while considering patient-specific factors that influence decision-making. Join this interactive session to challenge your clinical thinking, compare expert perspectives, and gain practical insights into some of the most difficult treatment decisions encountered in psychiatric practice.
Learning Objectives
- Compare the risks and benefits of antipsychotic polypharmacy versus clozapine monotherapy.
- Identify appropriate strategies for managing inadequate response to long-acting injectable antipsychotics, including assessment of adherence, drug levels, and augmentation options.
- Describe evidence-based and patient-centered considerations for antipsychotic treatment in complex clinical scenarios where guidelines offer limited direction.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Bob Haight, PharmD, BCPP (moderator)
Bio coming soon!
Amy Werremeyer, PharmD, BCPP
Amy Werremeyer is a tenured Professor and Department Chair in the School of Pharmacy at North Dakota State University (NDSU) in Fargo, ND. She is a BCPP with over 20 years of experience in psychiatric pharmacy practice with interdisciplinary teams in inpatient, partial hospital, and ambulatory psychiatry settings where she has provided drug information and consultation services, group patient education, and pharmacy student education in behavioral health. She currently practices at a community behavioral health center in the clozapine clinic.
Dr. Werremeyer’s research has traditionally focused on the study of patient experiences related to medications for treatment of mental illness and substance use disorders. She, along with a team of interprofessional colleagues from NDSU, is a researcher in the ONE Program (Opioid and Naloxone Education) that focuses on upstream prevention of opioid-related harms. Her current projects center on creation of methadone medication dispensing units in rural community pharmacies and MOUD stigma by workers in correctional settings. Dr. Werremeyer is passionate about reducing mental illness and substance use disorder stigma and works with an interdisciplinary team in sponsoring SNAP the Stigma, an engagement website for sharing and reflecting on lived experiences. She has received research funding from the NIH, ND Opioid Settlement Funds, and ND’s Rural Health Transformation Program, but has no other relationships to declare.
As a past president, she is proud to call AAPP her professional home. She also is active in the American Association of Colleges of Pharmacy and is currently participating as part of Cohort 23 in their Academic Leadership Fellowship Program.
Austin Campbell, PharmD, BCPP, FAAPP
Austin Campbell is a Clinical Associate Professor at the University of Missouri–Kansas City School of Pharmacy and an Adjunct Assistant Professor at the University of Missouri School of Medicine. He is a Board-Certified Psychiatric Pharmacist (BCPP) and Fellow of the American Association of Psychiatric Pharmacists (FAAPP), with more than 15 years of experience teaching psychopharmacology to students, residents, and fellows across multiple disciplines. For over a decade, he served as an inpatient Clinical Pharmacy Specialist in Psychiatry at the Missouri Psychiatric Center before transitioning to academia in 2022. Since that time, he has practiced as a psychiatric ambulatory care pharmacist within an internal medicine clinic.
He is widely published in peer-reviewed journals, has authored multiple book chapters on psychiatric treatment, and is a frequent speaker at national and state conferences. His contributions have been recognized with numerous honors, including Teacher of the Year in 2024 and 2025, Pharmacist of the Year from the Missouri Society of Health-System Pharmacists (MSHP) in 2025, and election to the American Association of Psychiatric Pharmacists Board of Directors as Member-at-Large beginning in 2026.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Dates: 4/4/2027-4/4/2029
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-##-###-###-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
View AAPP's Disclaimer and Disclosure Declarations
AAPP Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unlabeled Use Disclosure: Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. The faculty, planners, and American Association of Psychiatric Pharmacists do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
View AAPP's Copyright Statement, Terms of Use, and Policies
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View AAPP's Privacy Policy. AAPP's Terms of Use and other policies on education programs, resources, toolkits, and other web based content/offerings are available here.
View AAPP's Fair Balance and Integrity Statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.